Oral News and Research

RSS

Study results report no benefit from use of sunitinib, sorafenib among patients with kidney cancer

Research results highlighted today at the press conference of a major medical meeting report no benefit from the use of either Sutent (sunitinib) or Nexavar (sorafenib) among patients with locally advanced renal cell carcinoma at high risk of recurrence, the ECOG-ACRIN Cancer Research Group announced.

24 Feb 2015

Ferring announces European launch of CORTIMENT®MMX® (budesonide) for ulcerative colitis, and new data re-confirms safety and efficacy

Ferring Pharmaceuticals announced today the European launch of CORTIMENT®MMX® (budesonide), the first and only approved oral controlled release budesonide treatment for active mild-to-moderate ulcerative colitis (UC) where mesalazine (5-ASA) treatment is not sufficient.

23 Feb 2015

Taiho Oncology announces acceptance of TAS-102 NDA for review by FDA

Taiho Oncology, Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), today announced the New Drug Application (NDA) for TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), has been accepted for review by the U.S. Food and Drug Administration.

23 Feb 2015

Case Western dental researcher discovers new way to model how T cells cause inflammation in mice

Case Western Reserve University dental researcher Pushpa Pandiyan has discovered a new way to model how infection-fighting T cells cause inflammation in mice.

23 Feb 2015

Clinical data demonstrates safety, efficacy of vedolizumab for treatment of adults with UC and CD

Takeda Pharmaceuticals International GmbH today announced the presentation of data further demonstrating the efficacy and safety of vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD).

23 Feb 2015

Palbociclib extends progression-free survival in advanced breast cancer patients

Palbociclib, an investigational oral medication that works by blocking molecules responsible for cancer cell growth, is well tolerated and extends progression-free survival (PFS) in newly diagnosed, advanced breast cancer patients, including those whose disease has stopped responding to traditional endocrine treatments.

21 Feb 2015

Industrial Biotechnology presents insights on cellulose nanocrystal toxicity

Novel nanomaterials derived from cellulose have many promising industrial applications, are biobased and biodegradable, and can be produced at relatively low cost. Their potential toxicity--whether ingested, inhaled, on contact with the skin, or on exposure to cells within the body--is a topic of intense discussion, and the latest evidence and insights on cellulose nanocrystal toxicity are presented in a Review article in Industrial Biotechnology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

20 Feb 2015

HIV Prevention Trials Network launches two phase 2 studies to evaluate new HIV drugs

The HIV Prevention Trials Network has launched two new phase 2 studies, HPTN 076 and HPTN 077, which are designed to evaluate new drugs to protect people from getting infected with HIV.

19 Feb 2015

NIH-sponsored clinical trials examine safety, acceptability of HIV antiretroviral medicines

Two new clinical trials are examining the safety and acceptability of antiretroviral medicines administered via injection as a means of protecting against HIV infection. The studies are being funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, and conducted by the NIAID-funded HIV Prevention Trials Network (HPTN).

19 Feb 2015

Rutgers researchers study rare form of gum disease that affects African-American adolescents

Oral biologist Daniel H. Fine and his team at Rutgers School of Dental Medicine have tracked more than 2,500 Newark children since 2007 to chart the progression of a rare form of gum disease that afflicts African-American adolescents.

19 Feb 2015

Gut microbial metabolite of linoleic acid has suppressive effect on intestinal inflammation

Inflammatory bowel diseases (IBDs), including Crohn disease and ulcerative colitis, are hard to completely cure. Globally, IBDs affect more than 4 million people, today. However, Professor Soichi Tanabe (Graduate School of Biosphere Science, Hiroshima University) and his collaborators have demonstrated that 10-hydroxy-cis-12-octadecenoic acid (HYA), a gut microbial metabolite of linoleic acid, has a suppressive effect on intestinal inflammation.

19 Feb 2015

Lupin introduces new InspiraChamber VHC under strategic licensing agreement with InspiRX

Pharma Major Lupin Limited announced today that its US subsidiary, Lupin Pharmaceuticals Inc. (collectively Lupin) has launched the all new InspiraChamber Anti-Static Valved Holding Chamber (VHC) under a strategic licensing agreement with the New Jersey based respiratory research and development company InspiRX Inc.

19 Feb 2015

Regulus Therapeutics reports net loss of $22.2 million for fourth quarter 2014

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the fourth quarter and year ended December 31, 2014, including a summary of recent corporate highlights.

19 Feb 2015

Sugar intake and tooth decay: an interview with Professor Nigel Pitts

Globally, dental caries (the technical term for tooth decay) is the most prevalent non-communicable disease, affecting 80% of the global population. Healthy teeth support overall well-being, while dental caries can contribute to high levels of pain and anxiety, as well as leading to other medical problems.

18 Feb 2015

Actavis provides overview of standalone global pharmaceutical development pipeline

Actavis plc, during its Investor Meeting in New York, today provided a detailed look into its standalone global pharmaceutical development pipeline that supports the Company's long-term organic growth. The Company provided details regarding key development programs, including clinical data, development milestones and an overview of potential market opportunities, as well as an updated look at Actavis' world-class generics pipeline, which continues to hold an industry-leading position in First-to-File opportunities in the U.S.

18 Feb 2015

Caris Life Sciences announces record-setting revenue for 2014

Caris Life Sciences, a leading biosciences company focused on fulfilling the promise of precision medicine, today announced select year-end financial and operational results for 2014, which include record-setting revenue and continued case volume growth for its panomic, comprehensive tumor profiling service, Caris Molecular Intelligence.

18 Feb 2015

CTCA presents research on new cancer nutrition therapies at A.S.P.E.N. Clinical Nutrition Week

Several Cancer Treatment Centers of America clinicians presented research from studies evaluating new cancer nutrition techniques and therapies at the American Society for Parenteral and Enteral Nutrition Clinical Nutrition Week held in Long Beach, Calif., February 14-17, 2015. CTCA clinicians led a plenary session and an oral abstract presentation, and presented eight posters to Clinical Nutrition Week attendees.

18 Feb 2015

Eliglustat drug improves liver, spleen size and hemoglobin level in adults with Gaucher disease type 1

Among previously untreated adults with Gaucher disease type 1, a genetic disease in which there is improper metabolism due to a defect in an enzyme, treatment with the drug eliglustat resulted in significant improvements in liver and spleen size hemoglobin level, and platelet count, according to a study in the February 17 issue of JAMA.

18 Feb 2015

$Postmenopausal women susceptible to bone fractures may be at increased risk for gum disease$

Postmenopausal women susceptible to bone fractures may be at increased risk for gum disease

Postmenopausal women susceptible to bone fractures may also be a higher risk for gum disease, according to researchers at Case Western Reserve University School of Dental Medicine and Case/Cleveland Clinic Postmenopausal Health Collaboration.

18 Feb 2015

Innophos Holdings' net sales decrease 1% to $194 million in fourth quarter 2014

Innophos Holdings, Inc., a leading international producer of performance-critical and nutritional specialty ingredients, with applications in food, beverage, dietary supplements, pharmaceutical, oral care and industrial end markets, today announced its financial results for the fourth quarter and full year 2014.

18 Feb 2015

Oral News and Research

Study results report no benefit from use of sunitinib, sorafenib among patients with kidney cancer

Ferring announces European launch of CORTIMENT®MMX® (budesonide) for ulcerative colitis, and new data re-confirms safety and efficacy

Taiho Oncology announces acceptance of TAS-102 NDA for review by FDA

Case Western dental researcher discovers new way to model how T cells cause inflammation in mice

Clinical data demonstrates safety, efficacy of vedolizumab for treatment of adults with UC and CD

Palbociclib extends progression-free survival in advanced breast cancer patients

Industrial Biotechnology presents insights on cellulose nanocrystal toxicity

HIV Prevention Trials Network launches two phase 2 studies to evaluate new HIV drugs

NIH-sponsored clinical trials examine safety, acceptability of HIV antiretroviral medicines

Rutgers researchers study rare form of gum disease that affects African-American adolescents

Gut microbial metabolite of linoleic acid has suppressive effect on intestinal inflammation

Lupin introduces new InspiraChamber VHC under strategic licensing agreement with InspiRX

Regulus Therapeutics reports net loss of $22.2 million for fourth quarter 2014

Sugar intake and tooth decay: an interview with Professor Nigel Pitts

Actavis provides overview of standalone global pharmaceutical development pipeline

Caris Life Sciences announces record-setting revenue for 2014

CTCA presents research on new cancer nutrition therapies at A.S.P.E.N. Clinical Nutrition Week

Eliglustat drug improves liver, spleen size and hemoglobin level in adults with Gaucher disease type 1

Postmenopausal women susceptible to bone fractures may be at increased risk for gum disease

Innophos Holdings' net sales decrease 1% to $194 million in fourth quarter 2014

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News